Kaziatherapeutics.com

Facebook Share Google Plus Share Twitter Share LinkedIn Share Pinterest Share StumbleUpon Share Reddit Share E-Mail Share

  • IP Server: 54.79.107.72 (See full)
  • Location: Sydney Australia (See map)
  • Registed: 2017-08-22 (4 years, 100 days)
  • Ping: 10 ms
  • HostName: ec2-54-79-107-72.ap-southeast-2.compute.amazonaws.com
  • DNS Server: ns-1195.awsdns-21.org, ns-1850.awsdns-39.co.uk, ns-426.awsdns-53.com, ns-782.awsdns-33.net

Websites Hosted on 54.79.107.72

Tools Checker


  • Hostname: ec2-54-79-107-72.ap-southeast-2.compute.amazonaws.com
  • Country: Australia
  • City: Sydney
  • Postal: 2000
  • Latitude: -33.8591
  • Longitude: 151.2002
  • Email Abuse: No Emails

Port Scanner (IP: 54.79.107.72)

 › Ftp: 21
 › Ssh: 22
 › Telnet: 23
 › Smtp: 25
 › Dns: 53
 › Http: 80
 › Pop3: 110
 › Portmapper, rpcbind: 111
 › Microsoft RPC services: 135
 › Netbios: 139
 › Imap: 143
 › Ldap: 389
 › Https: 443
 › SMB directly over IP: 445
 › Msa-outlook: 587
 › IIS, NFS, or listener RFS remote_file_sharing: 1025
 › Lotus notes: 1352
 › Sql server: 1433
 › Point-to-point tunnelling protocol: 1723
 › My sql: 3306
 › Remote desktop: 3389
 › Session Initiation Protocol (SIP): 5060
 › Virtual Network Computer display: 5900
 › X Window server: 6001
 › Webcache: 8080

Top Keywords Suggestions

  › Kaziatherapeutics.com
  › Kazia therapeutics
  › Kazia therapeutics asx
  › Kazia therapeutics news
  › Kazia therapeutics stock
  › Kazia therapeutics limited
  › Kazia therapeutics market cap
  › Kazia therapeutics limited stock
  › Kazia therapeutics limited company

Top 10 related websites

Contact | Kazia Therapeutics Limited

Kazia Therapeutics Limited. Email: [email protected] Mailing Address. Kazia Therapeutics Limited. Three International Towers. Level 24, 300 Barangaroo Avenue. Sydney NSW 2000, Australia. Alternatively, contact us via the form below with your requirements and we will be in touch with a solution that is best for you.

DA: 25 PA: 24 MOZ Rank: 49

Go URL

Contact | Kazia Therapeutics Limited

Kazia Therapeutics Limited Three International Towers Level 24, 300 Barangaroo Avenue Sydney NSW 2000, Australia [email protected] https://www.kaziatherapeutics.com

DA: 25 PA: 34 MOZ Rank: 60

Go URL

Kazia Therapeutics Limited

Kazia is an Australian oncology company developing innovative, high-impact drugs for cancer. Our lead program is paxalisib, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.

DA: 25 PA: 25 MOZ Rank: 28

Go URL

About Us | Kazia Therapeutics Limited

Kazia Therapeutics Limited Three International Towers Level 24, 300 Barangaroo Avenue Sydney NSW 2000, Australia [email protected] https://www.kaziatherapeutics.com

DA: 25 PA: 24 MOZ Rank: 52

Go URL

For Investors | Kazia Therapeutics Limited

Kazia is an Australian oncology company developing innovative, high-impact drugs for cancer. Our lead program is paxalisib, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.

DA: 25 PA: 15 MOZ Rank: 44

Go URL

Kazia Therapeutics - Crunchbase Company Profile & …

Also Known As Novogen. Stock Symbol ASX:KZA. Company Type For Profit. Contact Email [email protected] Phone Number +61 2 9472 4100. Kazia Therapeutics is an oncology focused biotechnology company, developing innovative anti-cancer drugs. Kazia Therapeutics collaborates with leading scientists, clinicians and investors around the world.

DA: 18 PA: 21 MOZ Rank: 44

Go URL

Kazia Therapeutics Appoints John Friend, MD, as Chief

Nov 23, 2021 · SYDNEY, Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD

DA: 12 PA: 50 MOZ Rank: 44

Go URL

Kazia Therapeutics Appoints John Friend, MD, as Chief

Nov 15, 2021 · Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, a …

DA: 18 PA: 50 MOZ Rank: 43

Go URL

Kazia Therapeutics Appoints John Friend, MD, as Chief

Nov 15, 2021 · Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.

DA: 12 PA: 50 MOZ Rank: 42

Go URL

Recently Analyzed

Sensorso.com (0 seconds ago) / US

Lawfirmcs.kr (1 seconds ago) / KR

Sqcircle.com (1 seconds ago) / US

Kaziatherapeutics.com (1 seconds ago) / AU

Callineurope.com (1 seconds ago) / VG

Netlawinc.com (2 seconds ago) / US

Aqbh.com (3 seconds ago) / CN

Gemssensors.de (3 seconds ago) / US

Kanmin.lk (4 seconds ago) / DE

Graysonlegal.ca (5 seconds ago) / US

Eahardscape.com (6 seconds ago) / US

Cobaltfirearminstruction.com (7 seconds ago) / US